GLP-1 receptor agonist

Semaglutide

Sold as Ozempic, Wegovy — once weekly, subcutaneous injection.

Mean weight change · STEP 1

-14.9%

Placebo arm

-2.4%

Duration

68 wk

What the number means

Mean change in body weight at 68 weeks on 2.4 mg weekly, in adults with overweight or obesity without diabetes.

Trial averages are not a forecast for any individual. Response varies widely, the trial population was screened and supported in ways a subscription is not, and the figure describes people who stayed on the medication for the full period.

Worth knowing

  • The cardiovascular outcome data (SELECT) is the strongest argument for this molecule over a larger average weight change elsewhere.
  • The most widely stocked option, and the one most likely to be covered when coverage exists at all.
  • Available as separate diabetes and weight-management brands at different doses — they are not interchangeable at the pharmacy counter.

Approved for

Type 2 diabetes (Ozempic) and chronic weight management (Wegovy), with an added indication for reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity.